|
Vaccine Detail
ALVAC-NiV-G |
Vaccine Information |
- Vaccine Name: ALVAC-NiV-G
- Target Pathogen: Nipah virus
- Target Disease: Nipah virus disease
- Vaccine Ontology ID: VO_0004733
- Type: Recombinant vector vaccine
- Status: Research
- Host Species for Licensed Use: Baboon
- F fusion protein
gene engineering:
- Type: Recombinant vector construction
- Description: Canarypox virus-based vaccine vectors carrying the gene for NiV glycoprotein (ALVAC-G) or the fusion protein (ALVAC-F) (Weingartl et al., 2006).
- Detailed Gene Information: Click Here.
- G glycoprotein
gene engineering:
- Type: Recombinant protein preparation
- Description: Canarypox virus-based vaccine vectors carrying the gene for NiV glycoprotein (ALVAC-G) or the fusion protein (ALVAC-F) (Weingartl et al., 2006).
- Detailed Gene Information: Click Here.
- Vector:
- Preparation: Canarypox virus-based vaccine vectors carrying the gene for NiV glycoprotein (ALVAC-G) (Weingartl et al., 2006).
- Immunization Route: Intramuscular injection (i.m.)
|
Host Response |
Pig Response
- Vaccination Protocol: Four pigs per group were intramuscularly challenged, with either with 10^8 PFU each or in combination of (ALVAC-NiV-G and ALVAC-NiV-F) (Weingartl et al., 2006).
- Vaccine Immune Response Type: VO_0003057
- Challenge Protocol: The pigs were challenged with 2.5 x 10^5 PFU of NiV two weeks later (Weingartl et al., 2006).
- Efficacy: The combined ALVAC-F/G vaccine induced the highest levels of neutralization antibodies (2,560); despite the low neutralizing antibody levels in the F vaccinees (160), all vaccinated animals appeared to be protected against challenge (Weingartl et al., 2006).
|
References |
Weingartl et al., 2006: Weingartl HM, Berhane Y, Caswell JL, Loosmore S, Audonnet JC, Roth JA, Czub M. Recombinant nipah virus vaccines protect pigs against challenge. Journal of virology. 2006; 80(16); 7929-7938. [PubMed: 16873250].
|
|